Skip to main content

John Petrovich, Mark Davis, John Rossi, Matt Vincent, John Burcham, Terrie Pizzie, and Eric Lander

Premium

John Petrovich will be the CEO of Calando Pharmaceuticals, a new subsidiary of Arrowhead Research that will focus on commercializing therapeutic RNAi delivery technologies.

Other co-founders of Calando include Mark Davis, a professor of chemical engineering at the California Institute of Technology; John Rossi, a molecular geneticist at the City of Hope’s Beckman Research Institute; and Matt Vincent, a partner at the law firm Ropes & Gray.


John Burcham has joined Applied Biosystems as senior marketing manager for TaqMan SNP genotyping assays. He came to ABI from GE Healthcare, formerly Amersham, where he was strategic marketing manager for proteomics. Prior to that, he held technical specialist and marketing positions at Bio-Rad. Burcham holds a BA from the University of California, Berkeley.


Terrie Pizzie will become senior vice president of commercial operations at Biacore International starting March 1, the company said last week. Prior to joining the company, he was vice president Europe of Applied Biosystems. Before that, he was ABI’s director of sales and marketing in Europe.


Eric Lander will receive this year’s Public Understanding of Science and Technology award from the American Association for the Advancement of Science, AAAS said this month. He is the founding director of the Broad Institute of MIT and Harvard and a professor of biology at MIT, a professor of systems biology at Harvard Medical School, and a member of the Whitehead Institute for Biomedical Research. Lander holds a PhD in mathematics from Oxford University and an undergraduate degree in mathematics from Princeton University.

The Scan

US Supports Patent Waivers

NPR reports that the Biden Administration has announced its support for waiving intellectual property protections for SARS-CoV-2 vaccines.

Vaccines Versus Variants

Two studies find the Pfizer-BioNTech SARS-CoV-2 vaccine to be effective against viral variants, and Moderna reports on booster shots to combat variants.

CRISPR for What Ails You

The Wall Street Journal writes that CRISPR-based therapies could someday be used to treat common conditions like heart attacks.

Nature Papers Review Integration of Single-Cell Assay Data, Present Approach to Detect Rare Variants

In Nature this week: review of ways to integrate data from single-cell assays, and more.